Akoya Biosciences Analyst Ratings
Akoya Biosciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 97.53% | Piper Sandler | $11 → $8 | Maintains | Overweight |
| 11/13/2023 | 122.22% | Stephens & Co. | $14 → $9 | Maintains | Overweight |
| 10/24/2023 | 97.53% | Morgan Stanley | $15 → $8 | Maintains | Overweight |
| 10/16/2023 | 171.6% | Piper Sandler | $14 → $11 | Maintains | Overweight |
| 10/12/2023 | 72.84% | UBS | $12 → $7 | Maintains | Buy |
| 08/08/2023 | 270.37% | Morgan Stanley | $16 → $15 | Maintains | Overweight |
| 08/08/2023 | 295.06% | Stephens & Co. | → $16 | Reiterates | Overweight → Overweight |
| 05/10/2023 | 295.06% | Morgan Stanley | $17 → $16 | Maintains | Overweight |
| 03/21/2023 | 295.06% | Stephens & Co. | → $16 | Reiterates | → Overweight |
| 03/08/2023 | 319.75% | Morgan Stanley | $18 → $17 | Maintains | Overweight |
| 11/03/2022 | 369.14% | Capital One | → $19 | Initiates Coverage On | → Overweight |
| 10/06/2022 | 295.06% | Stephens & Co. | → $16 | Initiates Coverage On | → Overweight |
| 08/17/2022 | 319.75% | Piper Sandler | $14 → $17 | Maintains | Overweight |
| 06/22/2022 | 295.06% | BTIG | → $16 | Initiates Coverage On | → Buy |
| 05/16/2022 | 245.68% | Piper Sandler | $18 → $14 | Maintains | Overweight |
| 05/09/2022 | 344.44% | Morgan Stanley | $19 → $18 | Maintains | Overweight |
| 03/18/2022 | 344.44% | Piper Sandler | $23 → $18 | Maintains | Overweight |
| 03/15/2022 | 369.14% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
| 02/15/2022 | 393.83% | Morgan Stanley | $24 → $20 | Maintains | Overweight |
| 05/11/2021 | 517.28% | Canaccord Genuity | → $25 | Initiates Coverage On | → Buy |
| 05/11/2021 | 467.9% | JP Morgan | → $23 | Initiates Coverage On | → Overweight |
| 05/11/2021 | 591.36% | Piper Sandler | → $28 | Initiates Coverage On | → Overweight |
| 05/11/2021 | 541.98% | Morgan Stanley | → $26 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/13/2023 | 97.53% | 派珀·桑德勒 | 11 美元 → 8 美元 | 維護 | 超重 |
| 11/13/2023 | 122.22% | Stephens & Co. | 14 美元 → 9 美元 | 維護 | 超重 |
| 2023 年 10 月 24 日 | 97.53% | 摩根士丹利 | 15 美元 → 8 美元 | 維護 | 超重 |
| 2023 年 10 月 16 日 | 171.6% | 派珀·桑德勒 | 14 美元 → 11 美元 | 維護 | 超重 |
| 2023 年 12 月 10 日 | 72.84% | 瑞銀（UBS） | 12 美元 → 7 美元 | 維護 | 買 |
| 08/08/2023 | 270.37% | 摩根士丹利 | 16 美元 → 15 美元 | 維護 | 超重 |
| 08/08/2023 | 295.06% | Stephens & Co. | → 16 美元 | 重申 | 超重 → 超重 |
| 05/10/2023 | 295.06% | 摩根士丹利 | 17 美元 → 16 美元 | 維護 | 超重 |
| 03/21/2023 | 295.06% | Stephens & Co. | → 16 美元 | 重申 | → 超重 |
| 03/08/2023 | 319.75% | 摩根士丹利 | 18 美元 → 17 美元 | 維護 | 超重 |
| 11/03/2022 | 369.14% | 資本一號 | → 19 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2022 年 6 月 10 日 | 295.06% | Stephens & Co. | → 16 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 08/17/2022 | 319.75% | 派珀·桑德勒 | 14 美元 → 17 美元 | 維護 | 超重 |
| 06/22/2022 | 295.06% | BTIG | → 16 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/16/2022 | 245.68% | 派珀·桑德勒 | 18 美元 → 14 美元 | 維護 | 超重 |
| 05/09/2022 | 344.44% | 摩根士丹利 | 19 美元 → 18 美元 | 維護 | 超重 |
| 03/18/2022 | 344.44% | 派珀·桑德勒 | 23 美元 → 18 美元 | 維護 | 超重 |
| 2022 年 3 月 15 日 | 369.14% | 摩根士丹利 | 20 美元 → 19 美元 | 維護 | 超重 |
| 2022 年 2 月 15 日 | 393.83% | 摩根士丹利 | 24 美元 → 20 美元 | 維護 | 超重 |
| 05/11/2021 | 517.28% | Canaccord Genu | → 25 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/11/2021 | 467.9% | 摩根大通 | → 23 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 05/11/2021 | 591.36% | 派珀·桑德勒 | → 28 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 05/11/2021 | 541.98% | 摩根士丹利 | → 26 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for Akoya Biosciences (AKYA)?
Akoya Biosciences（AKYA）的目標價格是多少？
The latest price target for Akoya Biosciences (NASDAQ: AKYA) was reported by Piper Sandler on November 13, 2023. The analyst firm set a price target for $8.00 expecting AKYA to rise to within 12 months (a possible 97.53% upside). 10 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年11月13日公佈了阿科亞生物科學（納斯達克股票代碼：AKYA）的最新目標股價。該分析公司將目標股價定爲8.00美元，預計AKYA將在12個月內升至12個月內（可能上漲97.53％）。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Akoya Biosciences (AKYA)?
分析師對Akoya Biosciences（AKYA）的最新評級是多少？
The latest analyst rating for Akoya Biosciences (NASDAQ: AKYA) was provided by Piper Sandler, and Akoya Biosciences maintained their overweight rating.
派珀·桑德勒對Akoya Biosciences（納斯達克股票代碼：AKYA）的最新分析師評級由派珀·桑德勒提供，阿科亞生物科學維持增持評級。
When is the next analyst rating going to be posted or updated for Akoya Biosciences (AKYA)?
Akoya Biosciences（AKYA）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akoya Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akoya Biosciences was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Akoya Biosciences的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Akoya Biosciences的最新評級是在2023年11月13日發佈的，因此您應該預計下一個評級將在2024年11月13日左右公佈。
Is the Analyst Rating Akoya Biosciences (AKYA) correct?
分析師評級Akoya Biosciences（AKYA）是否正確？
While ratings are subjective and will change, the latest Akoya Biosciences (AKYA) rating was a maintained with a price target of $11.00 to $8.00. The current price Akoya Biosciences (AKYA) is trading at is $4.05, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Akoya Biosciences（AKYA）評級維持不變，目標股價爲11.00美元至8.00美元。Akoya Biosciences（AKYA）目前的交易價格爲4.05美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。